Colon Cancer is a leading cause of death in the United States. Accordingly, methods of preventing this disease or discovery of agents that increase effectiveness of existing chemotherapeutic agents would be very beneficial. Our studies and those of others have indicated that dietary curcumin, an active ingredient in the spice turmeric, potently inhibits intestinal tumorigenesis. We have now characterized the mechanisms by which curcumin modulates this function. Proliferation, angiogenesis and tumor invasiveness constitute the major pathways that are necessary for the growth and metastatic potential of cancer. Our preliminary studies show that curcumin inhibits cell proliferation, and tumor angiogenesis and invasiveness, while it enhances spontaneous and chemotherapy-induced apoptosis of tumor cells. The goals of the current project are to determine the mechanistic effects of curcumin on each of theses processes. Specifically, we will determine the effects of curcumin on growth factor-mediated activation of cellular signaling pathways. We will also determine the role of curcumin in signaling mediated by epidermal growth factor and prostaglandins, two molecules that are active in cancer progression. In addition, we will determine the effect of curcumin on the expression and regulation of tumor suppressor protein p53, an important regulator of cell survival. We will examine the effect of curcumin on expression of p53 target genes such as p21 WAF1, BAX. Moreover, we will examine the role of curcumin in the expression of VEGF and related angiogenesis factors as well as matrix metalloproteinases as regulators of tumor invasiveness. We will compare the results obtained in cell culture studies with that observed in mice with defined genetic manipulations. Together these studies should provide insight into the cancer process and how curcumin suppresses the risk and proliferation of colon cancer, and of no less importance, why curcumin is of great value as a food supplement. ? ?
| Snyder, Vusala; Reed-Newman, Tamika C; Arnold, Levi et al. (2018) Cancer Stem Cell Metabolism and Potential Therapeutic Targets. Front Oncol 8:203 |
| Kaushik, Gaurav; Venugopal, Anand; Ramamoorthy, Prabhu et al. (2015) Honokiol inhibits melanoma stem cells by targeting notch signaling. Mol Carcinog 54:1710-21 |
| Ramalingam, Satish; Subramaniam, Dharmalingam; Anant, Shrikant (2015) Manipulating miRNA Expression: A Novel Approach for Colon Cancer Prevention and Chemotherapy. Curr Pharmacol Rep 1:141-153 |
| Neradugomma, Naveen K; Subramaniam, Dharmalingam; Tawfik, Ossama W et al. (2014) Prolactin signaling enhances colon cancer stemness by modulating Notch signaling in a Jak2-STAT3/ERK manner. Carcinogenesis 35:795-806 |
| Kaushik, Gaurav; Kwatra, Deep; Subramaniam, Dharmalingam et al. (2014) Honokiol affects melanoma cell growth by targeting the AMP-activated protein kinase signaling pathway. Am J Surg 208:995-1002; discussion 1001-2 |
| Subramaniam, Dharmalingam; Thombre, Ravi; Dhar, Animesh et al. (2014) DNA methyltransferases: a novel target for prevention and therapy. Front Oncol 4:80 |
| Paul, Santanu; Ramalingam, Satish; Subramaniam, Dharmalingam et al. (2014) Histone Demethylases in Colon Cancer. Curr Colorectal Cancer Rep 10:417-424 |
| Kwatra, Deep; Subramaniam, Dharmalingam; Ramamoorthy, Prabhu et al. (2013) Methanolic extracts of bitter melon inhibit colon cancer stem cells by affecting energy homeostasis and autophagy. Evid Based Complement Alternat Med 2013:702869 |
| Kwatra, Deep; Venugopal, Anand; Standing, David et al. (2013) Bitter melon extracts enhance the activity of chemotherapeutic agents through the modulation of multiple drug resistance. J Pharm Sci 102:4444-54 |
| He, Zhiyun; Subramaniam, Dharmalingam; Zhang, Zhongtao et al. (2013) Honokiol as a Radiosensitizing Agent for Colorectal cancers. Curr Colorectal Cancer Rep 9: |
Showing the most recent 10 out of 46 publications
